Meta AnalysisID 1355
抗凝血酶、重组人活化蛋白C(rhAPC)和重组人可溶性血栓调节蛋白(rhTM)对脓毒症患者的疗效和安全性
CRD42014013886
The purpose of this systematic review and meta-analysis is to evaluate and compare the efficacy and safety of antithrombin and rhTM in the treatment of disseminated intravascular coagulation in patients with sepsis
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1355
- Evidence Id
- 9913
- Core Evidence Id
- 9913
- Source Meta Analysis Id
- 1314
- Herb2 Meta Analysis Id
- HBMA001314
- Crd Id
- CRD42014013886
- Title
- The efficacy and safety of antithrombin ,recombinant human activated protein C(rhAPC) and recombinant human soluble thrombomodulin (rhTM) on patients with sepsis
- Review Question
- The purpose of this systematic review and meta-analysis is to evaluate and compare the efficacy and safety of antithrombin and rhTM in the treatment of disseminated intravascular coagulation in patients with sepsis
- Study Type Included
- Randomed controled trials (RCT)
- Condition Being Studied
- In 2007, sepsis was recorded as the 10th leading cause of death in the US. In the US, there are as many as 750,000 to 900,000 cases per year, resulting in around 200,000 deaths per year. It has been reported that the interaction between the coagulation system and inflammatory reactions during severe sepsis will promote the progression of disseminated intravascular coagulation (DIC) and multiple organ failure. And the mortality rate of sepsis patients with DIC as high as 45%, whereas, the mortality rate of sepsis patients without DIC is 25%. Therefore anticoagulant therapy is of important for severe sepsis patients with DIC. A multi-center RCT reported that moderate doses of antithrombin could improve DIC score,and did not increase the risk of bleeding. In 2001, Bernard et al. reported that treatment with drotrecogin alfa activated ( recombinant human activated protein C ) significantly reduces mortality in patients with severe sepsis. And in recent years, rhTM has been reported may have a significant beneficial effect on mortality and other endpoints. However, up to recently, the efficacy and safety of the above mentioned three drugs have not yet been compared.
- Participant
- Patients with sepsis (of any severity).
- Animal
- Human Disease Modelled
- Intervention
- Receving recombinant human activated protein C or antithrombin or rhTM of any dose.
- Comparator Control
- Receving placebo or stand therapy (of any type)
- Main Outcome
- Mortality with the longest follow-up period and bleeding events (including minor or major).
- Outcome Measure
- Additional Outcome
- The length of ICU stay, the length of hospital stay, the duration of mechanical ventilation
- Study Method
- Keyword
- Anticoagulants; Antithrombins; Humans; Protein C; Recombinant Proteins; Sepsis; Thrombomodulin
- Contact
- Dr Jiang [email protected]
- Organisational Affiliation
- Second Affiliated Hospital, School of Medicine & Institute of Emergency Medicine, Zhejiang University http://www.z2hospital.com/
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2014-09-24
- Anticipated Start Date
- 2014-10-31
- Anticipated Completion Date
- 2015-10-31
- Title Cn
- 抗凝血酶、重组人活化蛋白C(rhAPC)和重组人可溶性血栓调节蛋白(rhTM)对脓毒症患者的疗效和安全性
- Title En
- The efficacy and safety of antithrombin ,recombinant human activated protein C(rhAPC) and recombinant human soluble thrombomodulin (rhTM) on patients with sepsis
- Bilingual Status
- complete